User login
Mr. J, age 52, has a history of opioid dependence. Four weeks after starting interferon therapy for hepatitis C, he presents to the outpatient mental health clinic with depressed mood, irritability, decreased energy, poor concentration, insomnia, anhedonia, and suicidal ideation.
Because Mr. J has no history of depression, the psychiatrist diagnoses him with depressive disorder secondary to interferon. Interferon is stopped. Mr. J’s mood improves, but he wants to restart interferon.
The psychiatrist starts Mr. J on sertraline, 50 mg/d, then gradually increases the dose to 150 mg/d as Mr. J’s mood symptoms return. Subsequently, the patient continues interferon with a combination of sertraline and supportive psychotherapy.
Recognizing a medication as the possible cause of your patient’s psychiatric symptoms can avoid inaccurate diagnosis and nonindicated psychiatric treatment. Diligently evaluating patients for drug-related psychiatric side effects is critical because complications usually are reversed when the offending drug is discontinued. Unfortunately, a thin line separates available evidence from anecdotal myths about psychiatric complications of nonpsychotropics.
Almost two-thirds (65%) of drugs included in the Physicians’ Desk Reference list potential psychiatric side effects, according to a random sample review.1 In some patients, such as Mr. J, these effects can exacerbate mood symptoms and result in perceptual, cognitive, or behavioral disturbances.
A wide range of drugs can cause psychosis, agitation, anxiety, depression, delirium, or insomnia (Table). On the other hand, certain psychiatric side effects of nonpsychotropics can be beneficial (Box 1).
Improve your assessments by examining the evidence linking psychiatric side effects to commonly prescribed and over-the-counter (OTC) compounds, including:
- cardiovascular medications
- steroids (prescription and illegal)
- hormones
- interferons
- antimicrobials.
Table
New-onset psychiatric symptoms? Check patient’s drug list
Symptom | Documented as a possible cause |
---|---|
Psychosis/agitation | Anabolic androgenic steroids, antihistamines, clonidine, corticosteroids, decongestants, didanosine, ethionamide, H2 blockers, isoniazid, nitrates, NSAIDs, opioids, proton pump inhibitors, quinolones, salbutamol, skeletal muscle relaxants, sulfonamides/trimethoprim |
Anxiety | Acyclovir, anabolic androgenic steroids, clonidine, corticosteroids, cyclosporine, decongestants, didanosine, serotonin 5-HT1 agonists such as sumatriptan, foscarnet, ganciclovir, nitrates, ondansetron, penicillins, skeletal muscle relaxants |
Depression | Anabolic androgenic steroids, beta blockers, chloramphenicol, clonidine, corticosteroids, didanosine, digoxin, efavirenz, foscarnet, GnRH agonists, H2 blockers, interferons, isoniazid, isotretinoin, NSAIDs, quinolones, statins, tetracyclines |
Delirium | ACE inhibitors, anabolic androgenic steroids, antibiotics (most), anticholinergics, beta blockers, centrally acting antihypertensives such as methyldopa and reserpine, cimetidine, clonidine, corticosteroids, didanosine, digoxin, H2 blockers, lidocaine, naltrexone, nitrates, NSAIDs, opioids |
Insomnia | Aminophylline, anabolic androgenic steroids, clonidine, corticosteroids, decongestants, didanosine, opioid antagonists, proton pump inhibitors, quinolone antibiotics, salbutamol, skeletal muscle relaxants, tetracyclines |
NSAIDs: nonsteroidal anti-inflammatory drugs; ACE: angiotensin-converting enzyme; GnRH: gonadotropin-releasing hormone | |
Source: Prepared for Current Psychiatry by Drs. Sidhu and Balon from references cited in this article |
Cardiovascular medications
Beta blockers have CNS effects—some of which cause psychiatric syndromes—that might depend on an ancillary property such as lipophilicity.2 Unlike hydrophilic agents such as atenolol that are excreted unchanged by the kidneys, lipophilic drugs such as metoprolol and propranolol are metabolized by the liver and are believed to enter the brain. Metoprolol has a brain/plasma concentration ratio about 20 times higher than that of atenolol.3
Metoprolol and propranolol can induce delirium and psychosis.4,5 Psychiatric side effects with metoprolol are frequent,4 and propranolol has been associated with:
- sedation (affecting >10% of patients)
- nightmares
- visual impairment
- hallucinations
- delirium
- depression.5
The relationship between depressive symptoms and beta blockers has been increasingly questioned, however. One study did not find a higher prevalence of depression in patients receiving beta blockers vs those receiving other medications, although this trial had major methodologic limitations.7 One large study found no significant association between beta-blocker use and major depression, regardless of patient age, gender, or race.8
These studies stress the importance of carefully assessing the individual patient before assigning neurotoxicity to beta blockers, as these drugs have considerable benefits for cardiovascular disease.9
Angiotensin-converting enzyme (ACE) inhibitors also affect the CNS. About 4% to 8% of patients taking an ACE inhibitor experience altered mental status—typically increased arousal and psychomotor activity—although
- anxiety
- mania
- insomnia
- fatigue
- paresthesias
- hallucinations.5
Clonidine is a centrally acting alpha-agonist. The alpha-adrenergic system regulates arousal and has an important role in major depression, anxiety states, and other arousal disorders.
More than one-third (35%) of patients taking clonidine experience sedation or lethargy; less commonly, the drug causes anxiety (3%), agitation (3%), depression (1%), and insomnia (1%).5 Acute confusion, delirium, hypomania, and psychosis related to clonidine use have long been recognized, occurring in 5
In some instances, mood-elevating side effects of nonpsychotropic medications might be beneficial. This might be the case if your patient experiences a sudden, otherwise unexplainable improvement.
CASE Helped by corticosteroids
Ms. Q, age 44, has a history of asthma and major depressive disorder and is being treated by a resident psychiatrist with a combination of paroxetine, 60 mg/d, mirtazapine, 15 mg at night, and cognitive-behavioral therapy. Her treatment has been challenging, and the psychiatrist has tried multiple medications and psychotherapy modalities.
At a recent psychotherapy session, Ms. Q says she has been feeling much better, with improved mood and greater energy. Upon further questioning, she reports having an asthma exacerbation a week before that resulted in hospitalization. During her stay, Ms. Q was started on a tapering dose of prednisone, which elevated her mood. Depressive symptoms returned when the effects of the prednisone wore off.
Prednisone is not indicated for depression and has harmful effects when used long term. The psychiatrist adds bupropion, 300 mg/d, to Ms. Q’s regimen, and her symptoms improve.
Cholesterol-lowering statins might be linked to an increased risk of depression and suicide, but the evidence is inconclusive. Some studies have supported this link,10,11 whereas others have strongly refuted it12,13 or had mixed results.14 A recent review15 recommends being vigilant for psychiatric side effects in patients taking these drugs.
Steroids: prescription and illegal
Corticosteroids are prescribed for a variety of immune system-related diseases, including asthma, allergic rhinitis, rheumatoid arthritis, inflammatory bowel disease, and dermatologic disorders. Mood changes are the most common psychiatric symptoms caused by corticosteroid use; delirium is less common. Psychiatric side effects include:
- lethargy
- insomnia
- euphoria
- depression
- psychosis
- “personality changes”
- anxiety
- agitation.5
A prospective study of asthma patients found statistically significant changes in mood—primarily manic symptoms—during brief corticosteroid courses at modest dosages. Depressed persons did not become more depressed during prednisone therapy, however; in fact, some improved. Some patients with posttraumatic stress disorder reported increased depression and memories of the traumatic event during prednisone therapy.17
In a study of 50 ophthalmologic patients who did not have psychiatric illness receiving prednisolone (mean starting dose 119 mg/d) for 8 days, 26% developed mania and 10% depression.18 None reported psychotic symptoms.
The most common adverse effects of short-term corticosteroid therapy are euphoria and hypomania. Long-term therapy tends to induce depressive symptoms.19 A review of 79 cases of psychiatric syndromes induced by corticosteroids found that 41% reported depression, 28% mania, 6% mixed symptoms, and 14% psychosis.20
A group of 16 healthy volunteers receiving 80 mg/d of prednisone over 5 days exhibited depressed or elevated mood, irritability, lability, increased energy, anxiety, and depersonalization.21 Numerous case studies have reported anxiety, agitation, mania, and psychotic symptoms in children and adults taking inhaled corticosteroids.
In general, psychiatric side effects of corticosteroids occur within 2 weeks of starting therapy and resolve with dosage reduction or discontinuation. In severe cases or situations in which the dosage cannot be reduced, the patient may require antipsychotics or mood stabilizers.19
Female gender and past psychiatric history might be risk factors for developing psychiatric symptoms with corticosteroids,22 although not all studies have confirmed these findings.18
Anabolic androgenic steroids (AAS) have limited therapeutic benefits but are used illegally by some bodybuilders, wrestlers, and other amateur and professional athletes to increase muscle mass, enhance performance, and gain a competitive edge. AAS can cause acute paranoia, delirium, mania or hypomania, homicidal rage, aggression, and extreme mood swings, as well as a marked increase in libido, irritability, agitation, and anger.
In a large observational cohort study of 320 bodybuilding amateur and recreational athletes,23 AAS use induced many of these psychiatric side effects. The extent intensified as the abuse escalated. A study that used the Structured Clinical Interview for DSM-III-R to compare 88 athletes using steroids with 68 nonusers found that 23% of the AAS users reported major mood syndromes, including mania, hypomania, and major depression.24
In a 2-week, double-blind, fixed-order, placebo-controlled, crossover study of healthy male inpatient volunteers, AAS had both:
- mood-elevating effects—euphoria (“steroid rush”), increased energy, and increased sexual arousal and drive
- mood-dysphoric effects, such as irritability, mood swings, increasingly violent feelings, increased hostility, and cognitive impairments.25
Hormones
Gonadotropin-releasing hormone (GnRH) agonists such as leuprolide and nafarelin are approved for treating endometriosis, advanced prostate cancer, precocious puberty, and uterine leiomyomata. Some studies and case reports suggest that these agents cause depressive symptoms.26
Interferon
Various forms of interferon are used to treat hepatitis C, melanoma, multiple sclerosis, chronic myelogenous leukemia, and other illnesses. Psychiatric complications—particularly depression—are the most frequent side effect of interferon therapy and mainly occur within the first 12 weeks of therapy.28
In a prospective observational study of veterans undergoing interferon-alfa/ribavirin treatment for chronic hepatitis C:
- 48% of patients not receiving psychiatric care at baseline required treatment for neuropsychiatric side effects
- 23% developed symptoms of major depression.29
Because patients who receive interferon are far more likely to require psychiatric intervention if they have a family history of mood disorders, closely monitor them for depressive symptoms and treat such symptoms aggressively. Also closely monitor patients with multiple psychiatric diagnoses receiving interferon-alfa therapy.30
Jeungling et al31 speculated that hypometabolism in the prefrontal cortex may predispose patients to interferon-associated neuropsychological syndromes. Neuropsychiatric symptoms may be a characteristic of hepatitis C, interferon treatment, or both.32
Antimicrobial agents
Antibiotic and antiviral drugs can cause psychiatric side effects:
- directly by affecting neuronal functions
- indirectly by entering the brain rapidly, taking advantage of the compromised blood-brain barrier during sepsis or infection.
Antibiotics. Penicillin and its analogues are associated with sedation, anxiety, and hallucinations. Delirium has been reported as a side effect of most cephalosporins, especially in patients with compromised renal function. Quinolones such as ciprofloxacin and ofloxacin rarely cause restlessness, irritability, lethargy, tremors, insomnia, mania, depression, psychosis, delirium, seizures, or catatonia (incidence ≤1%).5 Though not commonly used, chloramphenicol may cause depression, confusion, and delirium. Many case reports have strongly associated clarithromycin with delirium.33
Isoniazid is one of the most commonly used antibiotics that can cause psychiatric side effects; it has been linked to delirium, mania, depression, and psychosis. Ethionamide is associated with sedation, irritability, depression, restlessness, and psychosis. Tetracyclines have been known to cause depression, insomnia, and irritability at high dosages.
Sulfonamides can cause delirium. Psychosis and confusion also have been reported, especially when sulfa drugs are combined with trimethoprim.5
Antivirals. When used intravenously and at high doses, acyclovir and ganciclovir can cause lethargy, anxiety, hallucinations, and frank delirium.5 Foscarnet—an antiviral used to treat herpes viruses—can cause depression, anxiety, hallucinations, and aggressive irritability.
Didanosine—an antiretroviral agent to treat HIV infections—can cause lethargy (5% to 7% of patients), depression (2%), anxiety (2%), emotional lability (25%), delirium (2%), insomnia (1%), and psychotic delusions (1%).5 Efavirenz treatment may be associated with major depression and severe suicidal ideation.34 Tenofovir, a nucleotide reverse transcriptase inhibitor, has not been associated with psychiatric side effects.27
Antifungals. Psychiatric side effects are rare.
OTC and other agents
Many common nonprescription agents can cause psychiatric symptoms. The most frequently used classes include cold and allergy preparations, reflux medications, and analgesics (Box 2).5,35
Cold preparations. Combined antihistamines and decongestants—such as phenylpropanolamine, azatadine, loratadine, ephedrine, phenylephrine, pseudoephedrine, and naphazoline—can cause an atropine-like psychosis that typically manifests as confusion, disorientation, agitation, hallucinations, and memory problems. Decongestants can cause dangerously high levels of norepinephrine when combined with monoamine oxidase inhibitors (MAOIs) and are contraindicated in patients taking MAOIs. Ephedrine can induce restlessness, dysphoria, irritability, anxiety, and insomnia.
Reflux medications. Two primary classes of reflux medications are proton pump inhibitors (omeprazole and lansoprazole) and H2 receptor antagonists (famotidine, nizatidine, ranitidine, and cimetidine). Although generally considered to have a benign side-effect profile, these medications have been reported to cause serious neuropsychiatric complications—including mental confusion, agitation, depression, and hallucinations—mainly in geriatric patients with impaired hepatic-renal function.36 These occur in only 37
Time to onset of psychiatric side effects from H2 antagonists varies. Ranitidine can cause depression 4 to 8 weeks after treatment begins. Cimetidine has been reported to cause adverse events within 2 to 3 weeks and delirium within 24 to 48 hours.38 These effects usually resolve within 3 days of discontinuing the drug. Cimetidine is also associated with sexual dysfunction.
Other medications. Ondansetron is a 5-hydroxytryptamine subclass 3 (5-HT3) antagonist used for antiemetic therapy. In case reports, it has been strongly associated with anxiety.40 This association is complex, however, and studies are evaluating 5-HT3 receptor antagonists for the treatment of anxiety, depression, phobia, and schizophrenia.
Isotretinoin—a retinoid used for severe acne—can cause severe depression and suicidal behavior.41
Aminophylline and salbutamol are associated with agitation, insomnia, euphoria, and delirium. Methotrexate is known to cause personality changes, irritability, and delirium.27
Up to 70% of persons in Western countries use analgesics regularly, primarily for headaches, other specific pains, and febrile illness. Nonsteroidal anti-inflammatory drugs (NSAIDs)—including aspirin, naproxen, ibuprofen, and indomethacin—are efficacious and have a wide safety margin, but potentially serious psychiatric side effects can occur even when these drugs are taken in recommended doses.
Salicylate intoxication, which can present as frank delirium, often goes unrecognized. Any NSAID can produce delirium in the elderly. Case reports have also implicated NSAIDs in mania, psychosis, and depressive disorders with suicidal ideation.35
Opioids may cause sedation, psychic slowing, dysphoria, mood changes, psychosis, and delirium. Epidural administration of morphine may induce hallucinations and catatonia. Opioid antagonists—such as naloxone and, particularly, naltrexone—can induce dysphoria, fatigue, sleep disturbances, suicidality, hallucinations, and delirium. The serotonin 5-HT1 agonist sumatriptan (an antimigraine medication) has been associated with fatigue, anxiety, and panic disorder.5
Skeletal muscle relaxants such as baclofen and dantrolene may induce sleep disturbances, anxiety, agitation, mood disturbances, hallucinations, and delirium.
Treating drug-related mood effects
If you suspect a nonpsychotropic medication is causing your patient’s psychiatric symptoms, discuss this with the patient and the prescribing physician. Switching to another similar agent may be an option. If this is not possible:
- work closely with the patient’s primary physician
- treat mood symptoms with appropriate psychotropics.
- Turjanski N, Lloyd GG. Psychiatric side-effects of medications: recent developments. Advances in Psychiatric Treatment 2005;11:58-70.
- Brown TM, Stoudemire A. Psychiatric side effects of prescription and over-the-counter medications. Recognition and management. Washington, DC: American Psychiatric Publishing; 1998.
- Physicians’ Desk Reference. www.pdr.net.
- Acyclovir • Zovirax
- Aminophylline • Phyllocontin, Truphylline
- Atenolol • Tenormin
- Azatadine • Optimine
- Baclofen • Lioresal
- Chloramphenicol • Chloromycetin
- Cimetidine • Tagamet
- Ciprofloxacin • Cipro
- Clarithromycin • Biaxin
- Clonidine • Catapres
- Cyclosporine • Neoral, Sandimmune, others
- Dantrolene • Dantrium
- Didanosine • Videx
- Efavirenz • Sustiva
- Ethionamide • Trecator
- Famotidine • Pepcid
- Foscarnet • Foscavir
- Ganciclovir • Cytovene
- Indomethacin • Indocin
- Interferon alfa • Intron, Roferon
- Isoniazid • Nydrazid
- Isotretinoin • Accutane
- Lansoprazole • Prevacid
- Leuprolide • Lupron
- Lidocaine • Xylocaine, Xylocard
- Loratadine • Claritin
- Methotrexate • Rheumatrex, Trexall
- Methyldopa • Aldomet
- Metoprolol • Lopressor
- Mirtazapine • Remeron
- Nafarelin • Synarel
- Naloxone • Suboxone
- Naltrexone • Vivitrol
- Naphazoline • Naphcon-A, Clearine
- Naproxen • Aleve, others
- Nizatidine • Axid
- Ofloxacin • Floxin
- Omeprazole • Prilosec
- Ondansetron • Zofran
- Paroxetine • Paxil
- Peginterferon alfa • PEG-Intron, Pegasys
- Phenylephrine • Neo-Synephrine
- Prednisolone • Blephamide, Pred Forte, others
- Propranolol • Inderal
- Pseudoephedrine • Actifed, Sudafed
- Ranitidine • Zantac
- Reserpine • Serpasi
- Ribavirin • Copegus, Rebetol
- Salbutamol • Aerolin, Airomir, others
- Sertraline • Zoloft
- Sumatriptan • Imitrex
- Tenofovir • Viread
- Trimethoprim • Proloprim
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Smith DA. Psychiatric side effects of non-psychiatric drugs. S D J Med 1991;44(10):291-2.
2. Conant J, Engler R, Janowsky D, et al. Central nervous system side effects of beta-adrenergic blocking agents with high and low lipid solubility. J Cardiovasc Pharmacol 1989;13:656-61.
3. Cruickshank JM, Neil-Dwyer G. Beta-blocker brain concentrations in man. Eur J Clin Pharmacol 1985;28:21-3.
4. Sirois FJ. Visual hallucinations and metoprolol. Psychosomatics 2006;47(6):537-8.
5. Brown TM, Stoudemire A. Psychiatric side effects of prescription and over-the-counter medications. Recognition and management. Washington, DC: American Psychiatric Publishing; 1998.
6. Waal HF. Propranolol-induced depression (letter). Br Med J 1967;2:50.-
7. Carney RM, Rich MW, teVelde A, et al. Prevalence of major depressive disorder in patients receiving beta-blocker therapy versus other medications. Am J Med 1987;83(2):223-6.
8. Bright RA, Everitt DE. Beta-blockers and depression. Evidence against an association. JAMA 1992;267(13):1783-7.
9. Yudofsky SC. Beta-blockers and depression: the clinician’s dilemma. JAMA 1992;267:1826-7.
10. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 1994;308:373-9.
11. Morales K, Wittink M, Datto C, et al. Simvastatin causes changes in affective processes in elderly volunteers. J Am Geriatr Soc 2006;54(1):70-6.
12. Yang CC, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 2003;163(16):1926-32.
13. Callréus T, Agerskov Andersen U, Hallas J, et al. Cardiovascular drugs and the risk of suicide: a nested case-control study. Eur J Clin Pharmacol 2007;63(6):591-6.
14. Agostini JV, Tinetti ME, Han L, et al. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc 2007;55(3):420-5.
15. Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf 2007;30(3):195-201.
16. Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharm. Ther 1972;13:694-8.
17. Brown ES, Suppes T, Khan DA, Carmody TJ 3rd. Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol 2002;22:55-61.
18. Naber D, Sand P, Heigl B. Psychological and neuropsychological effects of 8 days’ corticosteroid treatment. A prospective study. Psychoneuroendocrinology 1996;21:25-31.
19. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006;81(10):1361-7.
20. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes: a report of 14 cases and a review of the literature. J Affect Disord 1983;5:319-32.
21. Wolkowitz OM, Rubinow D, Doran AR, et al. Prednisone effects on neurochemistry and behavior. Arch Gen Psych 1990;47:963-8.
22. Ling MHM, Perry PJ, Tsuang MT. Side effects of corticosteroid therapy. Arch Gen Psychiatry 1981;38:471-7.
23. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. Eur Psychiatry 2006;21(8):551-62.
24. Pope HG, Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use: a controlled study of 160 athletes. Arch Gen Psychiatry 1994;51:375-82.
25. Su T, Pagliaro M, Schmidt P, et al. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 1993;269:2760-4.
26. Warnock JK, Bundren JC, Morris DW. Depressive symptoms associated with gonadotropin-releasing hormone agonists. Depress Anxiety 1998;7:171-7.
27. Turjanski N, Lloyd GG. Psychiatric side-effects of medications: recent developments. Advances in Psychiatric Treatment 2005;11:58-70.
28. Lotrich FE, Rabinovitz M, Gironda P, Pollock BG. Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosom Res 2007;63(2):131-5.
29. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44(2):104-12.
30. Jakiche A, Paredez EC, Tannan PK, et al. Trend of depression and the use of psychiatric medications in U.S. Veterans with hepatitis C during interferon-based therapy. Am J Gastroenterol 2007;102(11):2426-33.
31. Juengling FD, Ebert D, Gut O, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology.(Berl) 2000;152:383-9.
32. Matthews SC, Paulus MP, Dimsdale JE. Contribution of functional neuroimaging to understanding neuropsychiatric side effects of interferon in hepatitis C. Psychosomatics 2004;45(4):281-6.
33. Ozsoylar G, Sayin A, Bolay H. Clarithromycin monotherapy-induced delirium. J Antimicrob Chemother 2007;59(2):331.-
34. Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy 2002;22:930-3.
35. Browning CH. Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. Int J Psychiatry Med 1996;26(1):25-34.
36. Picotte-Prillmayer D, DiMaggio JR, Baile WF. H2 blocker delirium. Psychosomatics 1995;36(1):74-7.
37. Cantu TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med 1991;114:1027-34.
38. Bernstein J. Handbook of drug therapy in psychiatry. St. Louis, MO: Mosby; 1995:380-1.
39. Rampello L, Nicoletti G. [The H2-antagonist therapy withdrawal syndrome: The possible role of hyperprolactinemia]. Medicina (Firenze) 1990;10:294-6.
40. Mitchell KE, Popkin MK, Trick W, Vercellotti G. Psychiatric complications associated with ondansetron. Psychosomatics 1994;35(2):161-3.
41. Brasic JR. Monitoring people treated with isotretinoin for depression. Psychol Rep 2007;100(3 Pt 2):1312-4.
Mr. J, age 52, has a history of opioid dependence. Four weeks after starting interferon therapy for hepatitis C, he presents to the outpatient mental health clinic with depressed mood, irritability, decreased energy, poor concentration, insomnia, anhedonia, and suicidal ideation.
Because Mr. J has no history of depression, the psychiatrist diagnoses him with depressive disorder secondary to interferon. Interferon is stopped. Mr. J’s mood improves, but he wants to restart interferon.
The psychiatrist starts Mr. J on sertraline, 50 mg/d, then gradually increases the dose to 150 mg/d as Mr. J’s mood symptoms return. Subsequently, the patient continues interferon with a combination of sertraline and supportive psychotherapy.
Recognizing a medication as the possible cause of your patient’s psychiatric symptoms can avoid inaccurate diagnosis and nonindicated psychiatric treatment. Diligently evaluating patients for drug-related psychiatric side effects is critical because complications usually are reversed when the offending drug is discontinued. Unfortunately, a thin line separates available evidence from anecdotal myths about psychiatric complications of nonpsychotropics.
Almost two-thirds (65%) of drugs included in the Physicians’ Desk Reference list potential psychiatric side effects, according to a random sample review.1 In some patients, such as Mr. J, these effects can exacerbate mood symptoms and result in perceptual, cognitive, or behavioral disturbances.
A wide range of drugs can cause psychosis, agitation, anxiety, depression, delirium, or insomnia (Table). On the other hand, certain psychiatric side effects of nonpsychotropics can be beneficial (Box 1).
Improve your assessments by examining the evidence linking psychiatric side effects to commonly prescribed and over-the-counter (OTC) compounds, including:
- cardiovascular medications
- steroids (prescription and illegal)
- hormones
- interferons
- antimicrobials.
Table
New-onset psychiatric symptoms? Check patient’s drug list
Symptom | Documented as a possible cause |
---|---|
Psychosis/agitation | Anabolic androgenic steroids, antihistamines, clonidine, corticosteroids, decongestants, didanosine, ethionamide, H2 blockers, isoniazid, nitrates, NSAIDs, opioids, proton pump inhibitors, quinolones, salbutamol, skeletal muscle relaxants, sulfonamides/trimethoprim |
Anxiety | Acyclovir, anabolic androgenic steroids, clonidine, corticosteroids, cyclosporine, decongestants, didanosine, serotonin 5-HT1 agonists such as sumatriptan, foscarnet, ganciclovir, nitrates, ondansetron, penicillins, skeletal muscle relaxants |
Depression | Anabolic androgenic steroids, beta blockers, chloramphenicol, clonidine, corticosteroids, didanosine, digoxin, efavirenz, foscarnet, GnRH agonists, H2 blockers, interferons, isoniazid, isotretinoin, NSAIDs, quinolones, statins, tetracyclines |
Delirium | ACE inhibitors, anabolic androgenic steroids, antibiotics (most), anticholinergics, beta blockers, centrally acting antihypertensives such as methyldopa and reserpine, cimetidine, clonidine, corticosteroids, didanosine, digoxin, H2 blockers, lidocaine, naltrexone, nitrates, NSAIDs, opioids |
Insomnia | Aminophylline, anabolic androgenic steroids, clonidine, corticosteroids, decongestants, didanosine, opioid antagonists, proton pump inhibitors, quinolone antibiotics, salbutamol, skeletal muscle relaxants, tetracyclines |
NSAIDs: nonsteroidal anti-inflammatory drugs; ACE: angiotensin-converting enzyme; GnRH: gonadotropin-releasing hormone | |
Source: Prepared for Current Psychiatry by Drs. Sidhu and Balon from references cited in this article |
Cardiovascular medications
Beta blockers have CNS effects—some of which cause psychiatric syndromes—that might depend on an ancillary property such as lipophilicity.2 Unlike hydrophilic agents such as atenolol that are excreted unchanged by the kidneys, lipophilic drugs such as metoprolol and propranolol are metabolized by the liver and are believed to enter the brain. Metoprolol has a brain/plasma concentration ratio about 20 times higher than that of atenolol.3
Metoprolol and propranolol can induce delirium and psychosis.4,5 Psychiatric side effects with metoprolol are frequent,4 and propranolol has been associated with:
- sedation (affecting >10% of patients)
- nightmares
- visual impairment
- hallucinations
- delirium
- depression.5
The relationship between depressive symptoms and beta blockers has been increasingly questioned, however. One study did not find a higher prevalence of depression in patients receiving beta blockers vs those receiving other medications, although this trial had major methodologic limitations.7 One large study found no significant association between beta-blocker use and major depression, regardless of patient age, gender, or race.8
These studies stress the importance of carefully assessing the individual patient before assigning neurotoxicity to beta blockers, as these drugs have considerable benefits for cardiovascular disease.9
Angiotensin-converting enzyme (ACE) inhibitors also affect the CNS. About 4% to 8% of patients taking an ACE inhibitor experience altered mental status—typically increased arousal and psychomotor activity—although
- anxiety
- mania
- insomnia
- fatigue
- paresthesias
- hallucinations.5
Clonidine is a centrally acting alpha-agonist. The alpha-adrenergic system regulates arousal and has an important role in major depression, anxiety states, and other arousal disorders.
More than one-third (35%) of patients taking clonidine experience sedation or lethargy; less commonly, the drug causes anxiety (3%), agitation (3%), depression (1%), and insomnia (1%).5 Acute confusion, delirium, hypomania, and psychosis related to clonidine use have long been recognized, occurring in 5
In some instances, mood-elevating side effects of nonpsychotropic medications might be beneficial. This might be the case if your patient experiences a sudden, otherwise unexplainable improvement.
CASE Helped by corticosteroids
Ms. Q, age 44, has a history of asthma and major depressive disorder and is being treated by a resident psychiatrist with a combination of paroxetine, 60 mg/d, mirtazapine, 15 mg at night, and cognitive-behavioral therapy. Her treatment has been challenging, and the psychiatrist has tried multiple medications and psychotherapy modalities.
At a recent psychotherapy session, Ms. Q says she has been feeling much better, with improved mood and greater energy. Upon further questioning, she reports having an asthma exacerbation a week before that resulted in hospitalization. During her stay, Ms. Q was started on a tapering dose of prednisone, which elevated her mood. Depressive symptoms returned when the effects of the prednisone wore off.
Prednisone is not indicated for depression and has harmful effects when used long term. The psychiatrist adds bupropion, 300 mg/d, to Ms. Q’s regimen, and her symptoms improve.
Cholesterol-lowering statins might be linked to an increased risk of depression and suicide, but the evidence is inconclusive. Some studies have supported this link,10,11 whereas others have strongly refuted it12,13 or had mixed results.14 A recent review15 recommends being vigilant for psychiatric side effects in patients taking these drugs.
Steroids: prescription and illegal
Corticosteroids are prescribed for a variety of immune system-related diseases, including asthma, allergic rhinitis, rheumatoid arthritis, inflammatory bowel disease, and dermatologic disorders. Mood changes are the most common psychiatric symptoms caused by corticosteroid use; delirium is less common. Psychiatric side effects include:
- lethargy
- insomnia
- euphoria
- depression
- psychosis
- “personality changes”
- anxiety
- agitation.5
A prospective study of asthma patients found statistically significant changes in mood—primarily manic symptoms—during brief corticosteroid courses at modest dosages. Depressed persons did not become more depressed during prednisone therapy, however; in fact, some improved. Some patients with posttraumatic stress disorder reported increased depression and memories of the traumatic event during prednisone therapy.17
In a study of 50 ophthalmologic patients who did not have psychiatric illness receiving prednisolone (mean starting dose 119 mg/d) for 8 days, 26% developed mania and 10% depression.18 None reported psychotic symptoms.
The most common adverse effects of short-term corticosteroid therapy are euphoria and hypomania. Long-term therapy tends to induce depressive symptoms.19 A review of 79 cases of psychiatric syndromes induced by corticosteroids found that 41% reported depression, 28% mania, 6% mixed symptoms, and 14% psychosis.20
A group of 16 healthy volunteers receiving 80 mg/d of prednisone over 5 days exhibited depressed or elevated mood, irritability, lability, increased energy, anxiety, and depersonalization.21 Numerous case studies have reported anxiety, agitation, mania, and psychotic symptoms in children and adults taking inhaled corticosteroids.
In general, psychiatric side effects of corticosteroids occur within 2 weeks of starting therapy and resolve with dosage reduction or discontinuation. In severe cases or situations in which the dosage cannot be reduced, the patient may require antipsychotics or mood stabilizers.19
Female gender and past psychiatric history might be risk factors for developing psychiatric symptoms with corticosteroids,22 although not all studies have confirmed these findings.18
Anabolic androgenic steroids (AAS) have limited therapeutic benefits but are used illegally by some bodybuilders, wrestlers, and other amateur and professional athletes to increase muscle mass, enhance performance, and gain a competitive edge. AAS can cause acute paranoia, delirium, mania or hypomania, homicidal rage, aggression, and extreme mood swings, as well as a marked increase in libido, irritability, agitation, and anger.
In a large observational cohort study of 320 bodybuilding amateur and recreational athletes,23 AAS use induced many of these psychiatric side effects. The extent intensified as the abuse escalated. A study that used the Structured Clinical Interview for DSM-III-R to compare 88 athletes using steroids with 68 nonusers found that 23% of the AAS users reported major mood syndromes, including mania, hypomania, and major depression.24
In a 2-week, double-blind, fixed-order, placebo-controlled, crossover study of healthy male inpatient volunteers, AAS had both:
- mood-elevating effects—euphoria (“steroid rush”), increased energy, and increased sexual arousal and drive
- mood-dysphoric effects, such as irritability, mood swings, increasingly violent feelings, increased hostility, and cognitive impairments.25
Hormones
Gonadotropin-releasing hormone (GnRH) agonists such as leuprolide and nafarelin are approved for treating endometriosis, advanced prostate cancer, precocious puberty, and uterine leiomyomata. Some studies and case reports suggest that these agents cause depressive symptoms.26
Interferon
Various forms of interferon are used to treat hepatitis C, melanoma, multiple sclerosis, chronic myelogenous leukemia, and other illnesses. Psychiatric complications—particularly depression—are the most frequent side effect of interferon therapy and mainly occur within the first 12 weeks of therapy.28
In a prospective observational study of veterans undergoing interferon-alfa/ribavirin treatment for chronic hepatitis C:
- 48% of patients not receiving psychiatric care at baseline required treatment for neuropsychiatric side effects
- 23% developed symptoms of major depression.29
Because patients who receive interferon are far more likely to require psychiatric intervention if they have a family history of mood disorders, closely monitor them for depressive symptoms and treat such symptoms aggressively. Also closely monitor patients with multiple psychiatric diagnoses receiving interferon-alfa therapy.30
Jeungling et al31 speculated that hypometabolism in the prefrontal cortex may predispose patients to interferon-associated neuropsychological syndromes. Neuropsychiatric symptoms may be a characteristic of hepatitis C, interferon treatment, or both.32
Antimicrobial agents
Antibiotic and antiviral drugs can cause psychiatric side effects:
- directly by affecting neuronal functions
- indirectly by entering the brain rapidly, taking advantage of the compromised blood-brain barrier during sepsis or infection.
Antibiotics. Penicillin and its analogues are associated with sedation, anxiety, and hallucinations. Delirium has been reported as a side effect of most cephalosporins, especially in patients with compromised renal function. Quinolones such as ciprofloxacin and ofloxacin rarely cause restlessness, irritability, lethargy, tremors, insomnia, mania, depression, psychosis, delirium, seizures, or catatonia (incidence ≤1%).5 Though not commonly used, chloramphenicol may cause depression, confusion, and delirium. Many case reports have strongly associated clarithromycin with delirium.33
Isoniazid is one of the most commonly used antibiotics that can cause psychiatric side effects; it has been linked to delirium, mania, depression, and psychosis. Ethionamide is associated with sedation, irritability, depression, restlessness, and psychosis. Tetracyclines have been known to cause depression, insomnia, and irritability at high dosages.
Sulfonamides can cause delirium. Psychosis and confusion also have been reported, especially when sulfa drugs are combined with trimethoprim.5
Antivirals. When used intravenously and at high doses, acyclovir and ganciclovir can cause lethargy, anxiety, hallucinations, and frank delirium.5 Foscarnet—an antiviral used to treat herpes viruses—can cause depression, anxiety, hallucinations, and aggressive irritability.
Didanosine—an antiretroviral agent to treat HIV infections—can cause lethargy (5% to 7% of patients), depression (2%), anxiety (2%), emotional lability (25%), delirium (2%), insomnia (1%), and psychotic delusions (1%).5 Efavirenz treatment may be associated with major depression and severe suicidal ideation.34 Tenofovir, a nucleotide reverse transcriptase inhibitor, has not been associated with psychiatric side effects.27
Antifungals. Psychiatric side effects are rare.
OTC and other agents
Many common nonprescription agents can cause psychiatric symptoms. The most frequently used classes include cold and allergy preparations, reflux medications, and analgesics (Box 2).5,35
Cold preparations. Combined antihistamines and decongestants—such as phenylpropanolamine, azatadine, loratadine, ephedrine, phenylephrine, pseudoephedrine, and naphazoline—can cause an atropine-like psychosis that typically manifests as confusion, disorientation, agitation, hallucinations, and memory problems. Decongestants can cause dangerously high levels of norepinephrine when combined with monoamine oxidase inhibitors (MAOIs) and are contraindicated in patients taking MAOIs. Ephedrine can induce restlessness, dysphoria, irritability, anxiety, and insomnia.
Reflux medications. Two primary classes of reflux medications are proton pump inhibitors (omeprazole and lansoprazole) and H2 receptor antagonists (famotidine, nizatidine, ranitidine, and cimetidine). Although generally considered to have a benign side-effect profile, these medications have been reported to cause serious neuropsychiatric complications—including mental confusion, agitation, depression, and hallucinations—mainly in geriatric patients with impaired hepatic-renal function.36 These occur in only 37
Time to onset of psychiatric side effects from H2 antagonists varies. Ranitidine can cause depression 4 to 8 weeks after treatment begins. Cimetidine has been reported to cause adverse events within 2 to 3 weeks and delirium within 24 to 48 hours.38 These effects usually resolve within 3 days of discontinuing the drug. Cimetidine is also associated with sexual dysfunction.
Other medications. Ondansetron is a 5-hydroxytryptamine subclass 3 (5-HT3) antagonist used for antiemetic therapy. In case reports, it has been strongly associated with anxiety.40 This association is complex, however, and studies are evaluating 5-HT3 receptor antagonists for the treatment of anxiety, depression, phobia, and schizophrenia.
Isotretinoin—a retinoid used for severe acne—can cause severe depression and suicidal behavior.41
Aminophylline and salbutamol are associated with agitation, insomnia, euphoria, and delirium. Methotrexate is known to cause personality changes, irritability, and delirium.27
Up to 70% of persons in Western countries use analgesics regularly, primarily for headaches, other specific pains, and febrile illness. Nonsteroidal anti-inflammatory drugs (NSAIDs)—including aspirin, naproxen, ibuprofen, and indomethacin—are efficacious and have a wide safety margin, but potentially serious psychiatric side effects can occur even when these drugs are taken in recommended doses.
Salicylate intoxication, which can present as frank delirium, often goes unrecognized. Any NSAID can produce delirium in the elderly. Case reports have also implicated NSAIDs in mania, psychosis, and depressive disorders with suicidal ideation.35
Opioids may cause sedation, psychic slowing, dysphoria, mood changes, psychosis, and delirium. Epidural administration of morphine may induce hallucinations and catatonia. Opioid antagonists—such as naloxone and, particularly, naltrexone—can induce dysphoria, fatigue, sleep disturbances, suicidality, hallucinations, and delirium. The serotonin 5-HT1 agonist sumatriptan (an antimigraine medication) has been associated with fatigue, anxiety, and panic disorder.5
Skeletal muscle relaxants such as baclofen and dantrolene may induce sleep disturbances, anxiety, agitation, mood disturbances, hallucinations, and delirium.
Treating drug-related mood effects
If you suspect a nonpsychotropic medication is causing your patient’s psychiatric symptoms, discuss this with the patient and the prescribing physician. Switching to another similar agent may be an option. If this is not possible:
- work closely with the patient’s primary physician
- treat mood symptoms with appropriate psychotropics.
- Turjanski N, Lloyd GG. Psychiatric side-effects of medications: recent developments. Advances in Psychiatric Treatment 2005;11:58-70.
- Brown TM, Stoudemire A. Psychiatric side effects of prescription and over-the-counter medications. Recognition and management. Washington, DC: American Psychiatric Publishing; 1998.
- Physicians’ Desk Reference. www.pdr.net.
- Acyclovir • Zovirax
- Aminophylline • Phyllocontin, Truphylline
- Atenolol • Tenormin
- Azatadine • Optimine
- Baclofen • Lioresal
- Chloramphenicol • Chloromycetin
- Cimetidine • Tagamet
- Ciprofloxacin • Cipro
- Clarithromycin • Biaxin
- Clonidine • Catapres
- Cyclosporine • Neoral, Sandimmune, others
- Dantrolene • Dantrium
- Didanosine • Videx
- Efavirenz • Sustiva
- Ethionamide • Trecator
- Famotidine • Pepcid
- Foscarnet • Foscavir
- Ganciclovir • Cytovene
- Indomethacin • Indocin
- Interferon alfa • Intron, Roferon
- Isoniazid • Nydrazid
- Isotretinoin • Accutane
- Lansoprazole • Prevacid
- Leuprolide • Lupron
- Lidocaine • Xylocaine, Xylocard
- Loratadine • Claritin
- Methotrexate • Rheumatrex, Trexall
- Methyldopa • Aldomet
- Metoprolol • Lopressor
- Mirtazapine • Remeron
- Nafarelin • Synarel
- Naloxone • Suboxone
- Naltrexone • Vivitrol
- Naphazoline • Naphcon-A, Clearine
- Naproxen • Aleve, others
- Nizatidine • Axid
- Ofloxacin • Floxin
- Omeprazole • Prilosec
- Ondansetron • Zofran
- Paroxetine • Paxil
- Peginterferon alfa • PEG-Intron, Pegasys
- Phenylephrine • Neo-Synephrine
- Prednisolone • Blephamide, Pred Forte, others
- Propranolol • Inderal
- Pseudoephedrine • Actifed, Sudafed
- Ranitidine • Zantac
- Reserpine • Serpasi
- Ribavirin • Copegus, Rebetol
- Salbutamol • Aerolin, Airomir, others
- Sertraline • Zoloft
- Sumatriptan • Imitrex
- Tenofovir • Viread
- Trimethoprim • Proloprim
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
Mr. J, age 52, has a history of opioid dependence. Four weeks after starting interferon therapy for hepatitis C, he presents to the outpatient mental health clinic with depressed mood, irritability, decreased energy, poor concentration, insomnia, anhedonia, and suicidal ideation.
Because Mr. J has no history of depression, the psychiatrist diagnoses him with depressive disorder secondary to interferon. Interferon is stopped. Mr. J’s mood improves, but he wants to restart interferon.
The psychiatrist starts Mr. J on sertraline, 50 mg/d, then gradually increases the dose to 150 mg/d as Mr. J’s mood symptoms return. Subsequently, the patient continues interferon with a combination of sertraline and supportive psychotherapy.
Recognizing a medication as the possible cause of your patient’s psychiatric symptoms can avoid inaccurate diagnosis and nonindicated psychiatric treatment. Diligently evaluating patients for drug-related psychiatric side effects is critical because complications usually are reversed when the offending drug is discontinued. Unfortunately, a thin line separates available evidence from anecdotal myths about psychiatric complications of nonpsychotropics.
Almost two-thirds (65%) of drugs included in the Physicians’ Desk Reference list potential psychiatric side effects, according to a random sample review.1 In some patients, such as Mr. J, these effects can exacerbate mood symptoms and result in perceptual, cognitive, or behavioral disturbances.
A wide range of drugs can cause psychosis, agitation, anxiety, depression, delirium, or insomnia (Table). On the other hand, certain psychiatric side effects of nonpsychotropics can be beneficial (Box 1).
Improve your assessments by examining the evidence linking psychiatric side effects to commonly prescribed and over-the-counter (OTC) compounds, including:
- cardiovascular medications
- steroids (prescription and illegal)
- hormones
- interferons
- antimicrobials.
Table
New-onset psychiatric symptoms? Check patient’s drug list
Symptom | Documented as a possible cause |
---|---|
Psychosis/agitation | Anabolic androgenic steroids, antihistamines, clonidine, corticosteroids, decongestants, didanosine, ethionamide, H2 blockers, isoniazid, nitrates, NSAIDs, opioids, proton pump inhibitors, quinolones, salbutamol, skeletal muscle relaxants, sulfonamides/trimethoprim |
Anxiety | Acyclovir, anabolic androgenic steroids, clonidine, corticosteroids, cyclosporine, decongestants, didanosine, serotonin 5-HT1 agonists such as sumatriptan, foscarnet, ganciclovir, nitrates, ondansetron, penicillins, skeletal muscle relaxants |
Depression | Anabolic androgenic steroids, beta blockers, chloramphenicol, clonidine, corticosteroids, didanosine, digoxin, efavirenz, foscarnet, GnRH agonists, H2 blockers, interferons, isoniazid, isotretinoin, NSAIDs, quinolones, statins, tetracyclines |
Delirium | ACE inhibitors, anabolic androgenic steroids, antibiotics (most), anticholinergics, beta blockers, centrally acting antihypertensives such as methyldopa and reserpine, cimetidine, clonidine, corticosteroids, didanosine, digoxin, H2 blockers, lidocaine, naltrexone, nitrates, NSAIDs, opioids |
Insomnia | Aminophylline, anabolic androgenic steroids, clonidine, corticosteroids, decongestants, didanosine, opioid antagonists, proton pump inhibitors, quinolone antibiotics, salbutamol, skeletal muscle relaxants, tetracyclines |
NSAIDs: nonsteroidal anti-inflammatory drugs; ACE: angiotensin-converting enzyme; GnRH: gonadotropin-releasing hormone | |
Source: Prepared for Current Psychiatry by Drs. Sidhu and Balon from references cited in this article |
Cardiovascular medications
Beta blockers have CNS effects—some of which cause psychiatric syndromes—that might depend on an ancillary property such as lipophilicity.2 Unlike hydrophilic agents such as atenolol that are excreted unchanged by the kidneys, lipophilic drugs such as metoprolol and propranolol are metabolized by the liver and are believed to enter the brain. Metoprolol has a brain/plasma concentration ratio about 20 times higher than that of atenolol.3
Metoprolol and propranolol can induce delirium and psychosis.4,5 Psychiatric side effects with metoprolol are frequent,4 and propranolol has been associated with:
- sedation (affecting >10% of patients)
- nightmares
- visual impairment
- hallucinations
- delirium
- depression.5
The relationship between depressive symptoms and beta blockers has been increasingly questioned, however. One study did not find a higher prevalence of depression in patients receiving beta blockers vs those receiving other medications, although this trial had major methodologic limitations.7 One large study found no significant association between beta-blocker use and major depression, regardless of patient age, gender, or race.8
These studies stress the importance of carefully assessing the individual patient before assigning neurotoxicity to beta blockers, as these drugs have considerable benefits for cardiovascular disease.9
Angiotensin-converting enzyme (ACE) inhibitors also affect the CNS. About 4% to 8% of patients taking an ACE inhibitor experience altered mental status—typically increased arousal and psychomotor activity—although
- anxiety
- mania
- insomnia
- fatigue
- paresthesias
- hallucinations.5
Clonidine is a centrally acting alpha-agonist. The alpha-adrenergic system regulates arousal and has an important role in major depression, anxiety states, and other arousal disorders.
More than one-third (35%) of patients taking clonidine experience sedation or lethargy; less commonly, the drug causes anxiety (3%), agitation (3%), depression (1%), and insomnia (1%).5 Acute confusion, delirium, hypomania, and psychosis related to clonidine use have long been recognized, occurring in 5
In some instances, mood-elevating side effects of nonpsychotropic medications might be beneficial. This might be the case if your patient experiences a sudden, otherwise unexplainable improvement.
CASE Helped by corticosteroids
Ms. Q, age 44, has a history of asthma and major depressive disorder and is being treated by a resident psychiatrist with a combination of paroxetine, 60 mg/d, mirtazapine, 15 mg at night, and cognitive-behavioral therapy. Her treatment has been challenging, and the psychiatrist has tried multiple medications and psychotherapy modalities.
At a recent psychotherapy session, Ms. Q says she has been feeling much better, with improved mood and greater energy. Upon further questioning, she reports having an asthma exacerbation a week before that resulted in hospitalization. During her stay, Ms. Q was started on a tapering dose of prednisone, which elevated her mood. Depressive symptoms returned when the effects of the prednisone wore off.
Prednisone is not indicated for depression and has harmful effects when used long term. The psychiatrist adds bupropion, 300 mg/d, to Ms. Q’s regimen, and her symptoms improve.
Cholesterol-lowering statins might be linked to an increased risk of depression and suicide, but the evidence is inconclusive. Some studies have supported this link,10,11 whereas others have strongly refuted it12,13 or had mixed results.14 A recent review15 recommends being vigilant for psychiatric side effects in patients taking these drugs.
Steroids: prescription and illegal
Corticosteroids are prescribed for a variety of immune system-related diseases, including asthma, allergic rhinitis, rheumatoid arthritis, inflammatory bowel disease, and dermatologic disorders. Mood changes are the most common psychiatric symptoms caused by corticosteroid use; delirium is less common. Psychiatric side effects include:
- lethargy
- insomnia
- euphoria
- depression
- psychosis
- “personality changes”
- anxiety
- agitation.5
A prospective study of asthma patients found statistically significant changes in mood—primarily manic symptoms—during brief corticosteroid courses at modest dosages. Depressed persons did not become more depressed during prednisone therapy, however; in fact, some improved. Some patients with posttraumatic stress disorder reported increased depression and memories of the traumatic event during prednisone therapy.17
In a study of 50 ophthalmologic patients who did not have psychiatric illness receiving prednisolone (mean starting dose 119 mg/d) for 8 days, 26% developed mania and 10% depression.18 None reported psychotic symptoms.
The most common adverse effects of short-term corticosteroid therapy are euphoria and hypomania. Long-term therapy tends to induce depressive symptoms.19 A review of 79 cases of psychiatric syndromes induced by corticosteroids found that 41% reported depression, 28% mania, 6% mixed symptoms, and 14% psychosis.20
A group of 16 healthy volunteers receiving 80 mg/d of prednisone over 5 days exhibited depressed or elevated mood, irritability, lability, increased energy, anxiety, and depersonalization.21 Numerous case studies have reported anxiety, agitation, mania, and psychotic symptoms in children and adults taking inhaled corticosteroids.
In general, psychiatric side effects of corticosteroids occur within 2 weeks of starting therapy and resolve with dosage reduction or discontinuation. In severe cases or situations in which the dosage cannot be reduced, the patient may require antipsychotics or mood stabilizers.19
Female gender and past psychiatric history might be risk factors for developing psychiatric symptoms with corticosteroids,22 although not all studies have confirmed these findings.18
Anabolic androgenic steroids (AAS) have limited therapeutic benefits but are used illegally by some bodybuilders, wrestlers, and other amateur and professional athletes to increase muscle mass, enhance performance, and gain a competitive edge. AAS can cause acute paranoia, delirium, mania or hypomania, homicidal rage, aggression, and extreme mood swings, as well as a marked increase in libido, irritability, agitation, and anger.
In a large observational cohort study of 320 bodybuilding amateur and recreational athletes,23 AAS use induced many of these psychiatric side effects. The extent intensified as the abuse escalated. A study that used the Structured Clinical Interview for DSM-III-R to compare 88 athletes using steroids with 68 nonusers found that 23% of the AAS users reported major mood syndromes, including mania, hypomania, and major depression.24
In a 2-week, double-blind, fixed-order, placebo-controlled, crossover study of healthy male inpatient volunteers, AAS had both:
- mood-elevating effects—euphoria (“steroid rush”), increased energy, and increased sexual arousal and drive
- mood-dysphoric effects, such as irritability, mood swings, increasingly violent feelings, increased hostility, and cognitive impairments.25
Hormones
Gonadotropin-releasing hormone (GnRH) agonists such as leuprolide and nafarelin are approved for treating endometriosis, advanced prostate cancer, precocious puberty, and uterine leiomyomata. Some studies and case reports suggest that these agents cause depressive symptoms.26
Interferon
Various forms of interferon are used to treat hepatitis C, melanoma, multiple sclerosis, chronic myelogenous leukemia, and other illnesses. Psychiatric complications—particularly depression—are the most frequent side effect of interferon therapy and mainly occur within the first 12 weeks of therapy.28
In a prospective observational study of veterans undergoing interferon-alfa/ribavirin treatment for chronic hepatitis C:
- 48% of patients not receiving psychiatric care at baseline required treatment for neuropsychiatric side effects
- 23% developed symptoms of major depression.29
Because patients who receive interferon are far more likely to require psychiatric intervention if they have a family history of mood disorders, closely monitor them for depressive symptoms and treat such symptoms aggressively. Also closely monitor patients with multiple psychiatric diagnoses receiving interferon-alfa therapy.30
Jeungling et al31 speculated that hypometabolism in the prefrontal cortex may predispose patients to interferon-associated neuropsychological syndromes. Neuropsychiatric symptoms may be a characteristic of hepatitis C, interferon treatment, or both.32
Antimicrobial agents
Antibiotic and antiviral drugs can cause psychiatric side effects:
- directly by affecting neuronal functions
- indirectly by entering the brain rapidly, taking advantage of the compromised blood-brain barrier during sepsis or infection.
Antibiotics. Penicillin and its analogues are associated with sedation, anxiety, and hallucinations. Delirium has been reported as a side effect of most cephalosporins, especially in patients with compromised renal function. Quinolones such as ciprofloxacin and ofloxacin rarely cause restlessness, irritability, lethargy, tremors, insomnia, mania, depression, psychosis, delirium, seizures, or catatonia (incidence ≤1%).5 Though not commonly used, chloramphenicol may cause depression, confusion, and delirium. Many case reports have strongly associated clarithromycin with delirium.33
Isoniazid is one of the most commonly used antibiotics that can cause psychiatric side effects; it has been linked to delirium, mania, depression, and psychosis. Ethionamide is associated with sedation, irritability, depression, restlessness, and psychosis. Tetracyclines have been known to cause depression, insomnia, and irritability at high dosages.
Sulfonamides can cause delirium. Psychosis and confusion also have been reported, especially when sulfa drugs are combined with trimethoprim.5
Antivirals. When used intravenously and at high doses, acyclovir and ganciclovir can cause lethargy, anxiety, hallucinations, and frank delirium.5 Foscarnet—an antiviral used to treat herpes viruses—can cause depression, anxiety, hallucinations, and aggressive irritability.
Didanosine—an antiretroviral agent to treat HIV infections—can cause lethargy (5% to 7% of patients), depression (2%), anxiety (2%), emotional lability (25%), delirium (2%), insomnia (1%), and psychotic delusions (1%).5 Efavirenz treatment may be associated with major depression and severe suicidal ideation.34 Tenofovir, a nucleotide reverse transcriptase inhibitor, has not been associated with psychiatric side effects.27
Antifungals. Psychiatric side effects are rare.
OTC and other agents
Many common nonprescription agents can cause psychiatric symptoms. The most frequently used classes include cold and allergy preparations, reflux medications, and analgesics (Box 2).5,35
Cold preparations. Combined antihistamines and decongestants—such as phenylpropanolamine, azatadine, loratadine, ephedrine, phenylephrine, pseudoephedrine, and naphazoline—can cause an atropine-like psychosis that typically manifests as confusion, disorientation, agitation, hallucinations, and memory problems. Decongestants can cause dangerously high levels of norepinephrine when combined with monoamine oxidase inhibitors (MAOIs) and are contraindicated in patients taking MAOIs. Ephedrine can induce restlessness, dysphoria, irritability, anxiety, and insomnia.
Reflux medications. Two primary classes of reflux medications are proton pump inhibitors (omeprazole and lansoprazole) and H2 receptor antagonists (famotidine, nizatidine, ranitidine, and cimetidine). Although generally considered to have a benign side-effect profile, these medications have been reported to cause serious neuropsychiatric complications—including mental confusion, agitation, depression, and hallucinations—mainly in geriatric patients with impaired hepatic-renal function.36 These occur in only 37
Time to onset of psychiatric side effects from H2 antagonists varies. Ranitidine can cause depression 4 to 8 weeks after treatment begins. Cimetidine has been reported to cause adverse events within 2 to 3 weeks and delirium within 24 to 48 hours.38 These effects usually resolve within 3 days of discontinuing the drug. Cimetidine is also associated with sexual dysfunction.
Other medications. Ondansetron is a 5-hydroxytryptamine subclass 3 (5-HT3) antagonist used for antiemetic therapy. In case reports, it has been strongly associated with anxiety.40 This association is complex, however, and studies are evaluating 5-HT3 receptor antagonists for the treatment of anxiety, depression, phobia, and schizophrenia.
Isotretinoin—a retinoid used for severe acne—can cause severe depression and suicidal behavior.41
Aminophylline and salbutamol are associated with agitation, insomnia, euphoria, and delirium. Methotrexate is known to cause personality changes, irritability, and delirium.27
Up to 70% of persons in Western countries use analgesics regularly, primarily for headaches, other specific pains, and febrile illness. Nonsteroidal anti-inflammatory drugs (NSAIDs)—including aspirin, naproxen, ibuprofen, and indomethacin—are efficacious and have a wide safety margin, but potentially serious psychiatric side effects can occur even when these drugs are taken in recommended doses.
Salicylate intoxication, which can present as frank delirium, often goes unrecognized. Any NSAID can produce delirium in the elderly. Case reports have also implicated NSAIDs in mania, psychosis, and depressive disorders with suicidal ideation.35
Opioids may cause sedation, psychic slowing, dysphoria, mood changes, psychosis, and delirium. Epidural administration of morphine may induce hallucinations and catatonia. Opioid antagonists—such as naloxone and, particularly, naltrexone—can induce dysphoria, fatigue, sleep disturbances, suicidality, hallucinations, and delirium. The serotonin 5-HT1 agonist sumatriptan (an antimigraine medication) has been associated with fatigue, anxiety, and panic disorder.5
Skeletal muscle relaxants such as baclofen and dantrolene may induce sleep disturbances, anxiety, agitation, mood disturbances, hallucinations, and delirium.
Treating drug-related mood effects
If you suspect a nonpsychotropic medication is causing your patient’s psychiatric symptoms, discuss this with the patient and the prescribing physician. Switching to another similar agent may be an option. If this is not possible:
- work closely with the patient’s primary physician
- treat mood symptoms with appropriate psychotropics.
- Turjanski N, Lloyd GG. Psychiatric side-effects of medications: recent developments. Advances in Psychiatric Treatment 2005;11:58-70.
- Brown TM, Stoudemire A. Psychiatric side effects of prescription and over-the-counter medications. Recognition and management. Washington, DC: American Psychiatric Publishing; 1998.
- Physicians’ Desk Reference. www.pdr.net.
- Acyclovir • Zovirax
- Aminophylline • Phyllocontin, Truphylline
- Atenolol • Tenormin
- Azatadine • Optimine
- Baclofen • Lioresal
- Chloramphenicol • Chloromycetin
- Cimetidine • Tagamet
- Ciprofloxacin • Cipro
- Clarithromycin • Biaxin
- Clonidine • Catapres
- Cyclosporine • Neoral, Sandimmune, others
- Dantrolene • Dantrium
- Didanosine • Videx
- Efavirenz • Sustiva
- Ethionamide • Trecator
- Famotidine • Pepcid
- Foscarnet • Foscavir
- Ganciclovir • Cytovene
- Indomethacin • Indocin
- Interferon alfa • Intron, Roferon
- Isoniazid • Nydrazid
- Isotretinoin • Accutane
- Lansoprazole • Prevacid
- Leuprolide • Lupron
- Lidocaine • Xylocaine, Xylocard
- Loratadine • Claritin
- Methotrexate • Rheumatrex, Trexall
- Methyldopa • Aldomet
- Metoprolol • Lopressor
- Mirtazapine • Remeron
- Nafarelin • Synarel
- Naloxone • Suboxone
- Naltrexone • Vivitrol
- Naphazoline • Naphcon-A, Clearine
- Naproxen • Aleve, others
- Nizatidine • Axid
- Ofloxacin • Floxin
- Omeprazole • Prilosec
- Ondansetron • Zofran
- Paroxetine • Paxil
- Peginterferon alfa • PEG-Intron, Pegasys
- Phenylephrine • Neo-Synephrine
- Prednisolone • Blephamide, Pred Forte, others
- Propranolol • Inderal
- Pseudoephedrine • Actifed, Sudafed
- Ranitidine • Zantac
- Reserpine • Serpasi
- Ribavirin • Copegus, Rebetol
- Salbutamol • Aerolin, Airomir, others
- Sertraline • Zoloft
- Sumatriptan • Imitrex
- Tenofovir • Viread
- Trimethoprim • Proloprim
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Smith DA. Psychiatric side effects of non-psychiatric drugs. S D J Med 1991;44(10):291-2.
2. Conant J, Engler R, Janowsky D, et al. Central nervous system side effects of beta-adrenergic blocking agents with high and low lipid solubility. J Cardiovasc Pharmacol 1989;13:656-61.
3. Cruickshank JM, Neil-Dwyer G. Beta-blocker brain concentrations in man. Eur J Clin Pharmacol 1985;28:21-3.
4. Sirois FJ. Visual hallucinations and metoprolol. Psychosomatics 2006;47(6):537-8.
5. Brown TM, Stoudemire A. Psychiatric side effects of prescription and over-the-counter medications. Recognition and management. Washington, DC: American Psychiatric Publishing; 1998.
6. Waal HF. Propranolol-induced depression (letter). Br Med J 1967;2:50.-
7. Carney RM, Rich MW, teVelde A, et al. Prevalence of major depressive disorder in patients receiving beta-blocker therapy versus other medications. Am J Med 1987;83(2):223-6.
8. Bright RA, Everitt DE. Beta-blockers and depression. Evidence against an association. JAMA 1992;267(13):1783-7.
9. Yudofsky SC. Beta-blockers and depression: the clinician’s dilemma. JAMA 1992;267:1826-7.
10. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 1994;308:373-9.
11. Morales K, Wittink M, Datto C, et al. Simvastatin causes changes in affective processes in elderly volunteers. J Am Geriatr Soc 2006;54(1):70-6.
12. Yang CC, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 2003;163(16):1926-32.
13. Callréus T, Agerskov Andersen U, Hallas J, et al. Cardiovascular drugs and the risk of suicide: a nested case-control study. Eur J Clin Pharmacol 2007;63(6):591-6.
14. Agostini JV, Tinetti ME, Han L, et al. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc 2007;55(3):420-5.
15. Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf 2007;30(3):195-201.
16. Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharm. Ther 1972;13:694-8.
17. Brown ES, Suppes T, Khan DA, Carmody TJ 3rd. Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol 2002;22:55-61.
18. Naber D, Sand P, Heigl B. Psychological and neuropsychological effects of 8 days’ corticosteroid treatment. A prospective study. Psychoneuroendocrinology 1996;21:25-31.
19. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006;81(10):1361-7.
20. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes: a report of 14 cases and a review of the literature. J Affect Disord 1983;5:319-32.
21. Wolkowitz OM, Rubinow D, Doran AR, et al. Prednisone effects on neurochemistry and behavior. Arch Gen Psych 1990;47:963-8.
22. Ling MHM, Perry PJ, Tsuang MT. Side effects of corticosteroid therapy. Arch Gen Psychiatry 1981;38:471-7.
23. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. Eur Psychiatry 2006;21(8):551-62.
24. Pope HG, Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use: a controlled study of 160 athletes. Arch Gen Psychiatry 1994;51:375-82.
25. Su T, Pagliaro M, Schmidt P, et al. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 1993;269:2760-4.
26. Warnock JK, Bundren JC, Morris DW. Depressive symptoms associated with gonadotropin-releasing hormone agonists. Depress Anxiety 1998;7:171-7.
27. Turjanski N, Lloyd GG. Psychiatric side-effects of medications: recent developments. Advances in Psychiatric Treatment 2005;11:58-70.
28. Lotrich FE, Rabinovitz M, Gironda P, Pollock BG. Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosom Res 2007;63(2):131-5.
29. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44(2):104-12.
30. Jakiche A, Paredez EC, Tannan PK, et al. Trend of depression and the use of psychiatric medications in U.S. Veterans with hepatitis C during interferon-based therapy. Am J Gastroenterol 2007;102(11):2426-33.
31. Juengling FD, Ebert D, Gut O, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology.(Berl) 2000;152:383-9.
32. Matthews SC, Paulus MP, Dimsdale JE. Contribution of functional neuroimaging to understanding neuropsychiatric side effects of interferon in hepatitis C. Psychosomatics 2004;45(4):281-6.
33. Ozsoylar G, Sayin A, Bolay H. Clarithromycin monotherapy-induced delirium. J Antimicrob Chemother 2007;59(2):331.-
34. Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy 2002;22:930-3.
35. Browning CH. Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. Int J Psychiatry Med 1996;26(1):25-34.
36. Picotte-Prillmayer D, DiMaggio JR, Baile WF. H2 blocker delirium. Psychosomatics 1995;36(1):74-7.
37. Cantu TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med 1991;114:1027-34.
38. Bernstein J. Handbook of drug therapy in psychiatry. St. Louis, MO: Mosby; 1995:380-1.
39. Rampello L, Nicoletti G. [The H2-antagonist therapy withdrawal syndrome: The possible role of hyperprolactinemia]. Medicina (Firenze) 1990;10:294-6.
40. Mitchell KE, Popkin MK, Trick W, Vercellotti G. Psychiatric complications associated with ondansetron. Psychosomatics 1994;35(2):161-3.
41. Brasic JR. Monitoring people treated with isotretinoin for depression. Psychol Rep 2007;100(3 Pt 2):1312-4.
1. Smith DA. Psychiatric side effects of non-psychiatric drugs. S D J Med 1991;44(10):291-2.
2. Conant J, Engler R, Janowsky D, et al. Central nervous system side effects of beta-adrenergic blocking agents with high and low lipid solubility. J Cardiovasc Pharmacol 1989;13:656-61.
3. Cruickshank JM, Neil-Dwyer G. Beta-blocker brain concentrations in man. Eur J Clin Pharmacol 1985;28:21-3.
4. Sirois FJ. Visual hallucinations and metoprolol. Psychosomatics 2006;47(6):537-8.
5. Brown TM, Stoudemire A. Psychiatric side effects of prescription and over-the-counter medications. Recognition and management. Washington, DC: American Psychiatric Publishing; 1998.
6. Waal HF. Propranolol-induced depression (letter). Br Med J 1967;2:50.-
7. Carney RM, Rich MW, teVelde A, et al. Prevalence of major depressive disorder in patients receiving beta-blocker therapy versus other medications. Am J Med 1987;83(2):223-6.
8. Bright RA, Everitt DE. Beta-blockers and depression. Evidence against an association. JAMA 1992;267(13):1783-7.
9. Yudofsky SC. Beta-blockers and depression: the clinician’s dilemma. JAMA 1992;267:1826-7.
10. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 1994;308:373-9.
11. Morales K, Wittink M, Datto C, et al. Simvastatin causes changes in affective processes in elderly volunteers. J Am Geriatr Soc 2006;54(1):70-6.
12. Yang CC, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 2003;163(16):1926-32.
13. Callréus T, Agerskov Andersen U, Hallas J, et al. Cardiovascular drugs and the risk of suicide: a nested case-control study. Eur J Clin Pharmacol 2007;63(6):591-6.
14. Agostini JV, Tinetti ME, Han L, et al. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc 2007;55(3):420-5.
15. Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf 2007;30(3):195-201.
16. Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharm. Ther 1972;13:694-8.
17. Brown ES, Suppes T, Khan DA, Carmody TJ 3rd. Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol 2002;22:55-61.
18. Naber D, Sand P, Heigl B. Psychological and neuropsychological effects of 8 days’ corticosteroid treatment. A prospective study. Psychoneuroendocrinology 1996;21:25-31.
19. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006;81(10):1361-7.
20. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes: a report of 14 cases and a review of the literature. J Affect Disord 1983;5:319-32.
21. Wolkowitz OM, Rubinow D, Doran AR, et al. Prednisone effects on neurochemistry and behavior. Arch Gen Psych 1990;47:963-8.
22. Ling MHM, Perry PJ, Tsuang MT. Side effects of corticosteroid therapy. Arch Gen Psychiatry 1981;38:471-7.
23. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. Eur Psychiatry 2006;21(8):551-62.
24. Pope HG, Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use: a controlled study of 160 athletes. Arch Gen Psychiatry 1994;51:375-82.
25. Su T, Pagliaro M, Schmidt P, et al. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 1993;269:2760-4.
26. Warnock JK, Bundren JC, Morris DW. Depressive symptoms associated with gonadotropin-releasing hormone agonists. Depress Anxiety 1998;7:171-7.
27. Turjanski N, Lloyd GG. Psychiatric side-effects of medications: recent developments. Advances in Psychiatric Treatment 2005;11:58-70.
28. Lotrich FE, Rabinovitz M, Gironda P, Pollock BG. Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosom Res 2007;63(2):131-5.
29. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44(2):104-12.
30. Jakiche A, Paredez EC, Tannan PK, et al. Trend of depression and the use of psychiatric medications in U.S. Veterans with hepatitis C during interferon-based therapy. Am J Gastroenterol 2007;102(11):2426-33.
31. Juengling FD, Ebert D, Gut O, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology.(Berl) 2000;152:383-9.
32. Matthews SC, Paulus MP, Dimsdale JE. Contribution of functional neuroimaging to understanding neuropsychiatric side effects of interferon in hepatitis C. Psychosomatics 2004;45(4):281-6.
33. Ozsoylar G, Sayin A, Bolay H. Clarithromycin monotherapy-induced delirium. J Antimicrob Chemother 2007;59(2):331.-
34. Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy 2002;22:930-3.
35. Browning CH. Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. Int J Psychiatry Med 1996;26(1):25-34.
36. Picotte-Prillmayer D, DiMaggio JR, Baile WF. H2 blocker delirium. Psychosomatics 1995;36(1):74-7.
37. Cantu TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med 1991;114:1027-34.
38. Bernstein J. Handbook of drug therapy in psychiatry. St. Louis, MO: Mosby; 1995:380-1.
39. Rampello L, Nicoletti G. [The H2-antagonist therapy withdrawal syndrome: The possible role of hyperprolactinemia]. Medicina (Firenze) 1990;10:294-6.
40. Mitchell KE, Popkin MK, Trick W, Vercellotti G. Psychiatric complications associated with ondansetron. Psychosomatics 1994;35(2):161-3.
41. Brasic JR. Monitoring people treated with isotretinoin for depression. Psychol Rep 2007;100(3 Pt 2):1312-4.